ThromboGenics, Alcon strike ocriplasmin marketing agreement
Under the agreement, ThromboGenics will receive an upfront payment of €75m, is also entitled to a further €90m in potential near-term milestone payments. In addition, ThromboGenics will receive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.